Firvanq Kit - (25mg/ml and 50mg/ml; Oral solution)

Generic Name	Vancomycin Hydrochloride	Innovator	Cutis (Azurity)
Dosage	25mg/ml and 50mg/ml; Oral solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Its a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of Clostridium difficile-associated diarrhea and Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains)
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ ***	*** **, ****	*** ** **	********	******** ** *** **, ****
*******	** \ **	-**-	*** ** ** / ********* ** ****** ** *******	****	****** **** ********
*********	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events